4 abstracts found.



Results filter

Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE(NCT00268476)

Year:

Session type:

Theme:

Nicholas D James1,13,Matthew R Sydes2,Malcolm D Mason3,Noel W Clarke14,David P Dearnaley4,Melissa R Spears2,Robin Millman15,Christopher C Parker8,Alastair W S Ritchie2,J Martin Russell5,John Staffurth11,Robert J Jones5,Shaun P Tolan6,John Wagstaff7,Andrew Protheroe8,Rajaguru Srinivasan9,Alison J Birtle10,Joe M O’Sullivan11,Richard Cathomas12,Mahesh K B Parmar2

1University of Warwick, Coventry, UK,2MRC Clinical Trials Unit at UCL, London, UK,3Velindre Hospital, Cardiff, UK,4The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK,5Beatson West of Scotland Cancer Centre, Glasgow, UK,6Clatterbridge Cancer Centre, Wirral, UK,7South West Wales Cancer Institute, Swansea, UK,8University of Oxford Medical Oncology Department, Oxford, UK,9Royal Devon and Exeter NHS Foundation Trust, Exeter, UK,10Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK,11Belfast City Hospital, Belfast, UK,12Kantonsspital Chur, Chur, Switzerland,13Queen Elizabeth Hospital, Birmingham, UK,14The Christie and Salford Royal Hospitals, Manchester, UK,15Prostate Cancer Support Group, Middlesbrough, UK


CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy treatment-naïve patients (pts) with advanced melanoma (MEL)

Year:

Session type:

Theme:

Jedd Wolchok1,Vanna Chiarion-Sileni2,Rene Gonzalez3,Piotr Rutkowski4,Jean Grob5,Charles Cowey6,Christopher Lao7,Dirk Schadendorf8,Pier Ferrucci9,Michael Smylie10,Reinhard Dummer11,Andrew Hill12,John Haanen13,Michele Maio14,Grant McArthur15,Arvin Yang16,Linda Rollin17,Christine Horak16,James Larkin18,Stephen Hodi19

1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA,2Oncology Institute of Veneto IRCCS, Padua, Italy,3University of Colorado Cancer Center, Denver, CO, USA,4Maria Sklodowska-Curie Memorial Cancer Center & Institute of Oncology, Warsaw, Poland,5Hospital de la Timone, Marseille, France,6Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA,7University of Michigan, Ann Arbor, MI, USA,8Department of Dermatology, University of Essen, Essen, Germany,9European Institute of Oncology, Milan, Italy,10Cross Cancer Institute, Edmonton, AB, Canada,11Universitäts Spital, Zurich, Switzerland,12Tasman Oncology Research, Queensland, Australia,13Netherlands Cancer Institute, Amsterdam, The Netherlands,14Medical Oncology and Immunotherapy, University Hospital of Siena, Siena, Italy,15Peter MacCallum Cancer Centre, Victoria, Australia,16Bristol-Myers Squibb, Princeton, NJ, USA,17Bristol-Myers Squibb, Wallingford, CT, USA,18Royal Marsden Hospital, London, UK,19Dana-Farber Cancer Institute, Boston, MA, USA


PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT)

Year:

Session type:

Theme:

Hisham Mehanna1,Wai Lup Wong2,Christopher A McConkey3,Joy K Rahman3,Max Robinson4,Andrew Hartley5,Christopher Nutting6,Ned Powell7,Hoda Al-Booz8,Martin Robinson9,Elizabeth Junor10,Claire Hulme11,Alison F Smith11,Peter Hall12,Bal Sanghera2,Janet A Dunn3

1InHANSE, University of Birmingham, Birmingham, UK,2Paul Strickland Scanner Centre, Mount Vernon Hospital, Middlesex, UK,3Warwick University Clinical Trials Unit, Coventry, UK,4Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle, UK,5Queen Elizabeth Hospital Birmingham, Birmingham, UK,6Royal Marsden Hospital, London, UK,7HPV Oncology Group, Institute of Cancer Genetics, Cardiff University, Cardiff, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9Weston Park Hospital, Sheffield, UK,10Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK,11University of Leeds, Leeds, UK,12St James University Hospital, Leeds, UK


A phase II/III randomised trial comparing maintenance lapatinib vs placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer

Year:

Session type:

Theme:

Simon Chowdhury2,Tony Elliot3,Robert Jones4,Syed Hussain5,Simon Crabb6,Charlotte Ackerman1,Satinder Jagdev7,John Chester7,Serena Hilman8,Mark Beresford8,Graham Macdonald9,Sundar Santhanam10,John Frew11,Andrew Stockdale12,Shah-Jalal Sarker1,Dan Berney1,Thomas Powles1,Robert Huddart13

1Barts Cancer Institute, London, UK,2Guy’s and St Thomas’ Hospital NHS Trust, London, UK,3The Christie NHS Foundation Trust, Manchester, UK,4Beatson West of Scotland Cancer Centre, Glasgow, UK,5The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK,6University Hospital Southampton NHS Foundation Trust, Southampton, UK,7St James’s University Hospital, Leeds, UK,8Bristol Haematology and Oncology Centre, Bristol, UK,9Aberdeen Royal Infirmary, Aberdeen, UK,10Nottingham University Hospitals NHS Trust, Nottingham, UK,11Freeman Hospital, Newcastle, UK,12University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK,13Royal Marsden Hospital, Surrey, UK